A study looking at the effectiveness of a oral herbal supplement for helping to manage the symptoms of enlarged prostate

INTERVENTION: Per Capsule Prunus Africanum stem bark: 15,000mg Cucubita pepo seed oil: 160mg Epilobium parviflorum: 500mg Seronoa repens seed: 660mg Lycopene: 2.1mg Excipients: Lecithin Vegetable oil Beeswax Soya oil Gelatin Capsules with glycerol, Opatint Blue and Opatint White Dosage One capsule (oral) per day before meals for 12 weeks duration. CONDITION: Benign Prostatic Hypertrophy PRIMARY OUTCOME: A reduction in the International Prostate Symptom Score (IPSS) to assess efficacy of preparation on symptoms of benign prostatic hypertrophy SECONDARY OUTCOME: Assess ability of herbal preparation in strengthening urinary flow aassess through scoring on the IPSS questionnaire. Assess effect of herbal preparation in reducing freqeuncy of urination any time of the day assessed through scoring on IPSS queestionnaire. Assess effect of herbal preparation in reducing the frequency of stopping and starting several time during urination assessed through scoring on the IPSS questionnaire. Assess effect of herbal preparation in reducing the sensation of not emptying bladder completely after finished urinating assessed through scoring on IPSS questionnaire. Assess effect of herbal preparation on serum prostate specific antigen (PSA) levels (pathology testing). Assess the effect of the herbal preparation in improving symptoms of pushing or straining to begin urination assess through scoring on the IPSS questionnaire. Assess the effect of the herbal preparation in improving the ability to postpone urination assessed through scoring on the IPSS questionnaire. Assess the effect of the herbal preparation in reducing the frequency of night time urination assessed through scoring on the IPSS questionnaire. Evaluate saftey and tolerability of herbal preparation assessed through patient diaries and reports of side effects and through Liver Function Tests (LFT) (pathology testing) and electrolytes (pathology testing). INCLUSION CRITERIA: 1. Male aged between 40‐80 years 2. Medically diagnosed with benign prostatic hypertrophy 3. Minimum score of 8 on the IPSS